News & Events

The Sydney Neuroimaging Analysis Centre (SNAC), a leading innovator in neuroimaging technology, today announced the receipt of CUREator+ funding to accelerate the development and clinical validation of its groundbreaking AI-powered MRI analysis platform for dementia care.

Dementia, including Alzheimer’s disease and mild cognitive impairment (MCI), remains one of the most pressing health challenges of our time. Early detection and precise monitoring are critical to improving patient outcomes, yet traditional radiology reports often fall short in identifying subtle, early-stage changes and complications associated with new therapies.

SNAC’s advanced, hardware-agnostic platform seamlessly integrates with existing clinical workflows, empowering clinicians with actionable insights beyond standard imaging. The platform uses state-of-the-art artificial intelligence and informatics to detect early signs of disease progression. New features detect (regulatory approvals pending) complications linked to emerging MCI and Alzheimer’s therapies, supporting timely, personalised care for patients.

“Securing CUREator+ funding is a pivotal milestone for SNAC,” said John Moulden, CCO of SNAC. “Our mission is to bridge the gap between advanced neuroimaging and clinical decision-making, equipping healthcare providers with the tools they need to deliver proactive, precision care to people living with dementia.”

The CUREator+ grant will enable SNAC to:

• Advance new product development to expand our current portfolio, enhancing diagnostic accuracy and usability, delivering this transformative technology to clinicians and patients across Australia and beyond.
• Conduct multi-centre clinical studies to validate the platform’s effectiveness in real-world settings.

By combining precision imaging with robust informatics, SNAC delivers clinical imaging support previously unavailable through standard approaches. This initiative underscores SNAC’s commitment to reshaping the future of dementia care, enabling earlier intervention, optimised treatment strategies, and improved quality of life for patients and their families.

About Sydney Neuroimaging Analysis Centre (SNAC):
SNAC is a leading medical technology company based in New South Wales, Australia. It is dedicated to advancing neuroimaging through cutting-edge AI solutions. SNAC partners with clinicians and researchers to deliver innovative tools that enhance diagnostic accuracy and patient care.

Media Contact:
John Moulden
Chief Commercial Officer
Sydney Neuroimaging Analysis Centre
Phone: +61 2 9055 1713
Email: PR@snac.com.au
Website: www.snac.com.au